mFOLFOX 6

DRUG4 trials

Sponsors

Boehringer Ingelheim, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Chungnam National University Hospital, Fudan University

Conditions

Colon Cancer Stage IIIColorectal CancerColorectal NeoplasmsLiver MetastasesStomach Neoplasms

Phase 2

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

CompletedNCT00904839

Boehringer IngelheimColorectal Neoplasms

Start: 2009-05-31End: 2012-01-31Updated: 2015-02-04

Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer

RecruitingNCT05179889

Chungnam National University HospitalColon Cancer Stage III

Start: 2021-07-06End: 2031-03-15Target: 308Updated: 2026-03-19

Phase 3

Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoStomach Neoplasms

Start: 2016-12-31End: 2021-12-31Target: 280Updated: 2021-09-13

Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM

Not yet recruitingNCT05948072

Fudan UniversityColorectal Cancer, Liver Metastases

Start: 2023-07-15End: 2026-07-15Target: 250Updated: 2023-07-17

Related Papers

Health-related quality of life (HRQoL) with paclitaxel plus ramucirumab (PTX-RAM) switch maintenance versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: A secondary endpoint of the ARMANI phase 3 randomized trial.

Journal of Clinical Oncology2025-05-281 citations

Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.

2024-11-1516 citations

Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.

Journal of Clinical Oncology2024-06-055 citations

mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer - the FROST trial: study protocol for a multicenter, randomized controlled, phase II trial

BMC Cancer2024-03-294 citations

mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer (FROST trial): Study protocol for an open label, multicenter, randomized, phase II study.

Journal of Clinical Oncology2024-01-20

Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.

Journal of Clinical Oncology2019-05-20

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.

2019-03-2912 citations